Pharmaceutical and Biotechnology companies are anticipated to fuel the growth of the global molecular modeling market at a CAGR of 15.93% during the forecast period of 2021 to 2027
Global Molecular Modelling Market is expected to register a CAGR of 15.93% during the forecast period 2021-2027, to reach USD 1,617.80 million by 2027.
“Global Molecular Modelling Market information from 2018 to 2027″considers the following companies as the key players in the global molecular modeling market—Simulations Plus, Inc (US), Cambridge Crystallographic Data Centre (England), Optibrium(UK), Cresset (UK), BioSolveIT GmbH (Germany), OpenEye Scientific Software (US), Chemical Computing Group(Canada), Acellera Ltd (London), Dassault Systèmes(France), Schrödinger, LLC(US), and Certara, L.P (US).
Market Highlights
The global molecular modeling market is expected to have a value of USD 1,617.80 million by 2027.
Molecular modeling is a collection of (computer-based) techniques for inventing, representing, and operating the structures and reactions of molecules. This technique even detects the properties dependent on the three-dimensional structures of the molecules. It also includes all theoretical methods and computational techniques used to mimic and study the structure and behavior of molecules, ranging from small chemical systems to large biological molecules and material assemblies. The growth of the global market is driven by the factors such as the increasing investment by the pharmaceutical and biotechnology companies in R&D.The increasing incidences of diseases such as cancer, cardiovascular disorders,and infections,as well as ongoing technological advancements,are expected to boost the growth of this market.
Segment Analysis
The global molecular modeling market is segmented into product, application, and end user. The product segment is further bifurcated into software and services. The application segment is further segmented into drug development, drug discovery, and others. Drug discovery is further sub-segmented into direct drug design,indirect drug design,and molecular mimicry. The end user segment is further segmented into pharmaceutical and biotechnology companies, research and academic centers,and others.
Regional Analysis
The global molecular modeling market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East &Africa.
The Americas dominated the global molecular modeling market with the largest share of 40% in 2020 due to the increasing adoption of products. The regional market is divided into North America and South America. North America consists of the US and Canada. The presence of technologically advanced infrastructure, rising adoption of innovative products, and the increasing number of companies involved in research activities are driving the growth of the market in this region. The presence of prominent research institutes and academic organizations promoting open access for research scientists further contributes to the growth of the market in the region.
Europe accounted for a market size of USD 173.29 million in 2020 and is expected to exhibit a CAGR of 15.70% during the forecast period. It is the second-largest market after the Americas. The highly developed healthcare industry, prominent research and development infrastructure, and accessibility of services for research purposes are the key factors influencing the market growth. The European molecular modeling market is segmented into Western Europe and Eastern Europe. Western Europe is further segmented into Germany, France, the UK, Spain, Italy, and the Rest of Western Europe. The molecular modeling market in Europe is expected to propel owing to factors such as a rise in the number of research funding and an increasing number of clinical trials related to computational techniques and theoretical methods used to model or mimic the behavior of molecules.
The molecular modeling marketin Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. It is the third-largest market and is anticipated to be the fastest-growing regional market owing to the increasing disposable income, a growing number of research institutes, an increasing number of contract research organizations, and improving healthcare infrastructure. The increasing outsourcing activities in the region for initial drug discovery solutions, bio-analytical services, biostatistics for oncology, cardiovascular diseases, immune disorders, infectious diseases, and other indications is expected to increase the market share of this region exponentially.Increased clinical trials related to the study of protein structures, computational biology, and biopharmaceuticals is also anticipated to increase the market size of the region.
The Middle East & Africa is further bifurcated into the Middle East and Africa. The regional market is expected to grow gradually owing to the rise in the monetary status and increasing online retailing. The large endemicity of certain infectious diseases causing strains and rising antimicrobial resistance leads to an increased study towards containing transmission.
Key Findings of the Study
-
- The global molecular modeling marketis estimated to reach USD 1,617.80 million by 2027 at a CAGR of 15.93% during the assessment period of 2021 to 2027
-
- The Americas accounted for the largest global market sharedue to the several collaborations undertaken by prominent market players for increasing the R&D activities and high medical standards.
-
- Based on product, the software segment accounted for the largest market share of 59.9% in 2020.
-
- Based on application, thedrug discovery segment held the highest share of 57.1% in 2020and is estimated to be the fastest-growing segment at a CAGR of 16.73%during the forecast period.
-
- Basis on end user, thepharmaceutical & biotechnology companies segment held the highest share of 47.7%, and the research & academic centers segment is projected to be the fastest-growing segment during the forecast period at a CAGR of 17.02%.
-
- Some of themajor market players are Simulations Plus, Inc (US), Cambridge Crystallographic Data Centre (England), Optibrium (UK), Cresset (UK), BioSolveIT GmbH (Germany), OpenEye Scientific Software (US), Chemical Computing Group (Canada), Acellera Ltd (London), Dassault Systèmes (France), Schrödinger, LLC (US), and Certara, L.P (US).